Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 49

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 49
---
 the SEC if we offer subscription rights. For more information on how you can obtain copies of the applicable subscription right agreement if we offer subscription rights, see “Where You Can Find More Information” beginning on page 28 and “Documents Incorporated by Reference” beginning on page 29. We urge you to read the applicable subscription right agreement and any applicable prospectus supplement in their entirety.

<div align='center'>21

DESCRIPTION OF WARRANTS</div>

We may issue warrants for the purchase of shares of our Common Stock. We may issue warrants independently of or together with shares of our Common Stock offered by any prospectus supplement, and we may attach the warrants to, or issue them separately from, shares of our Common Stock. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the prospectus supplement relating to the particular issue of offered warrants. The warrant agent will act solely as our agent in connection with the warrant certificates relating to the warrants and will not assume any obligation or relationship of agency or trust with any holders of warrant certificates or beneficial owners of warrants. The following summaries of certain provisions of the warrant agreements and warrants do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all the provisions of the warrant agreement and the warrant certificates relating to each series of warrants which we will file with the SEC and incorporate by reference as an exhibit to the registration statement of which this prospectus is a part at or prior to the time of the issuance of any series of warrants.

General

The applicable prospectus supplement will describe the terms of the warrants, including as applicable:

| ● | the             
 offering price; |

| ● | the                                                                                                                   
 aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price; |

| ● | the                               
 number of warrants being offered; |

| ● | the                                                                                                   
 date, if any, after which the warrants and the underlying securities will be transferable separately; |

| ● | the                                                                                                                                  
 date on which the right to exercise the warrants will commence, and the date on which the right will expire, or the Expiration Date; |

| ● | the                                     
 number of warrants outstanding, if any; |

| ● | any                                                            
 material Canadian and/or U.S. federal income tax consequences; |

| ● | the                                                                                              
 terms, if any, on which we may accelerate the date by which the